NCT07156539 - A Phase 3 Study of HS-20094 in Patients With T2DM | Biotech Hunter

Enrollment

546

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

May 30, 2027

Conditions

Type 2 Diabetes

Interventions

DRUG

HS-20094 Injection

HS-20094 injected subcutaneously once weekly

DRUG

Dulaglutide Injection

Dulaglutide injected subcutaneously once weekly

Trial Locations (2)

Shandong Provincial Hospital, Jinan

Tianjin Medical University General Hospital (Zhu Xianyi Memorial Hospital), Tianjin